[go: up one dir, main page]

NO20081038L - Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering - Google Patents

Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering

Info

Publication number
NO20081038L
NO20081038L NO20081038A NO20081038A NO20081038L NO 20081038 L NO20081038 L NO 20081038L NO 20081038 A NO20081038 A NO 20081038A NO 20081038 A NO20081038 A NO 20081038A NO 20081038 L NO20081038 L NO 20081038L
Authority
NO
Norway
Prior art keywords
guanfacine
compositions
dosage form
pharmaceutical formulations
single dosage
Prior art date
Application number
NO20081038A
Other languages
English (en)
Inventor
Amir Shojaei
Michael Pennick
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37668083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081038(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Llc filed Critical Shire Llc
Publication of NO20081038L publication Critical patent/NO20081038L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Terapeutiske formuleringer av guanfacin i en én gang om dagen enkeltdoseform som har formålstjenlige generelle tablettstørrelser er beskrevet.
NO20081038A 2005-07-28 2008-02-27 Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering NO20081038L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70298205P 2005-07-28 2005-07-28
PCT/US2006/029277 WO2007016284A2 (en) 2005-07-28 2006-07-27 Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily

Publications (1)

Publication Number Publication Date
NO20081038L true NO20081038L (no) 2008-04-23

Family

ID=37668083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081038A NO20081038L (no) 2005-07-28 2008-02-27 Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering

Country Status (18)

Country Link
US (1) US20070048371A1 (no)
EP (1) EP1909766B1 (no)
JP (2) JP5726401B2 (no)
KR (1) KR20080041669A (no)
CN (1) CN101252917A (no)
AR (1) AR054595A1 (no)
AU (1) AU2006275718B8 (no)
BR (1) BRPI0615989B8 (no)
CA (1) CA2616181C (no)
DK (1) DK1909766T3 (no)
ES (1) ES2566395T3 (no)
IL (1) IL188980A0 (no)
NO (1) NO20081038L (no)
NZ (1) NZ565649A (no)
RU (1) RU2435573C2 (no)
TW (1) TW200744672A (no)
WO (1) WO2007016284A2 (no)
ZA (1) ZA200801575B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0916163D0 (en) * 2009-09-15 2009-10-28 Shire Llc Prodrugs of guanfacine
JP6045347B2 (ja) * 2010-02-03 2016-12-14 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用
US20110313046A1 (en) * 2010-06-11 2011-12-22 Ermer James Combination therapy with lisdexamphetamine and extended release guanfacine
US20120041068A1 (en) * 2010-08-11 2012-02-16 Aptapharma, Inc. Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility
CN102525983A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 胍法新缓释片及其制备方法
CN102579381B (zh) * 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
US9180104B2 (en) * 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
AU2014240988B9 (en) 2013-03-13 2019-01-03 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
US10022341B2 (en) 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
AU2016368622B2 (en) * 2015-12-08 2022-09-08 Ardea Biosciences, Inc. Pharmaceutical composition comprising a potent inhibitor of URAT1
JP6656670B2 (ja) * 2016-03-11 2020-03-04 国立大学法人 鹿児島大学 抗ｈｃｖ活性を有する薬剤
NZ746669A (en) * 2016-04-20 2022-10-28 New Frontier Labs Llc Azelaic acid esters in the treatment of insulin resistance
WO2019136224A1 (en) * 2018-01-05 2019-07-11 Shire Human Genetic Therapies, Inc. Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders
JP2023035359A (ja) * 2021-09-01 2023-03-13 東和薬品株式会社 グアンファシン製剤
EP4292587A1 (en) 2022-06-15 2023-12-20 Sawai Pharmaceutical Co., Ltd. Guanfacine hydrochloride containing pharmaceutical preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649918A5 (de) * 1981-07-09 1985-06-28 Sandoz Ag Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
DE19834573A1 (de) * 1998-07-31 2000-02-03 Bayer Ag Doppelmetallcyanid-Katalysatoren für die Herstellung von Polyetherpolyolen
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US6635277B2 (en) * 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
WO2003051340A1 (en) * 2001-12-19 2003-06-26 Astrazeneca Ab New film coating
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AU2003224794A1 (en) * 2002-03-29 2003-10-13 Alza Corporation Volume efficient controlled release dosage form
US6763509B2 (en) * 2002-09-26 2004-07-13 Sun Microsystems, Inc. Method and apparatus for allocating decoupling capacitor cells
US20070104782A1 (en) * 2005-07-28 2007-05-10 Ibrahim Melissa E Modified release tablet formulations with enhanced mechanical properties

Also Published As

Publication number Publication date
TW200744672A (en) 2007-12-16
AU2006275718B2 (en) 2012-10-04
BRPI0615989B8 (pt) 2021-05-25
US20070048371A1 (en) 2007-03-01
CA2616181C (en) 2015-02-17
AU2006275718A1 (en) 2007-02-08
AR054595A1 (es) 2007-06-27
RU2008102911A (ru) 2009-09-10
ES2566395T3 (es) 2016-04-12
BRPI0615989A2 (pt) 2011-05-31
JP2009502951A (ja) 2009-01-29
WO2007016284A2 (en) 2007-02-08
RU2435573C2 (ru) 2011-12-10
JP5726401B2 (ja) 2015-06-03
IL188980A0 (en) 2008-08-07
CN101252917A (zh) 2008-08-27
BRPI0615989B1 (pt) 2020-05-26
CA2616181A1 (en) 2007-02-08
EP1909766B1 (en) 2016-03-16
EP1909766A2 (en) 2008-04-16
ZA200801575B (en) 2008-12-31
AU2006275718B8 (en) 2012-11-01
WO2007016284A3 (en) 2007-03-29
DK1909766T3 (en) 2016-04-04
NZ565649A (en) 2011-03-31
JP2012229253A (ja) 2012-11-22
KR20080041669A (ko) 2008-05-13
AU2006275718A8 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
NO20081038L (no) Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering
AU2008347158A8 (en) Oral pharmaceutical dosage forms
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
SV2009003231A (es) Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o implementar la libido femenina
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
UA116334C2 (uk) Тверді форми дозування бендамустину
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
AR025938A1 (es) Nuevas composiciones farmaceuticas.
CR20110704A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica
EA201170512A1 (ru) Композиция для перорального введения
DK1987063T3 (da) Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
EP4238556A4 (en) GASTRORETENTIVE PHARMACEUTICAL DOSAGE FORM
DE602007004348D1 (de) Arzneimittel zur behandlung von sarkoglykanopathien
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
EA201290378A1 (ru) Композиции, содержащие нестероидные противовоспалительные лекарственные средства
GB0327390D0 (en) Pharmaceutical formulations
TR200704897A1 (tr) Uzatılmış salım sağlayan gliklazid formülasyonları@
HK40090884A (en) Gastroretentive pharmaceutical dosage form
CL2012003685A1 (es) Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application